
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

CureVac N.V.

(Name of Issuer)

Common Shares, par value (euro)0.12 per share

(Title of Class of Securities)

N2451R105

(CUSIP Number)

Brian S. North, Esquire
Buchanan Ingersoll & Rooney PC, 50 South 16th Street, Suite 3200
Philadelphia, PA, 19102
(215) 665-8700

Dr. Christina Eschenfelder
RITTERSHAUS, Harrlachweg 4
Mannheim, 2M, 68163
49 621 4256-275

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

12/10/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. N2451R105

1 Name of reporting person
 MH-LT-Investments GmbH
 Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
 Source of funds (See Instructions)

4 OO
 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

6 Citizenship or place of organization
 GERMANY

7 Sole Voting Power
 0.00

Number of Shares Beneficially Owned by Each Reporting Person With:

8 Shared Voting Power
 0.00

9 Sole Dispositive Power
 0.00

10 Shared Dispositive Power
 0.00

11 Aggregate amount beneficially owned by each reporting person
 0.00

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13 Percent of class represented by amount in Row (11)
 0.00 %

14 Type of Reporting Person (See Instructions)
 OO

SCHEDULE 13D

CUSIP No. N2451R105

1 Name of reporting person
 Dr. Matthias Hothum
 Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
 Source of funds (See Instructions)

4 OO

5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)



Citizenship or place of organization

6

GERMANY

Sole Voting Power

7

0.00

Number of
Shares

Shared Voting Power

Beneficially 8

Owned by

0.00

Each

Sole Dispositive Power

Reporting 9

Person

0.00

With:

Shared Dispositive Power

10

0.00

Aggregate amount beneficially owned by each reporting person

11

0.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12



Percent of class represented by amount in Row (11)

13

0.00 %

Type of Reporting Person (See Instructions)

14

IN

SCHEDULE 13D

Item 1. Security and Issuer

Title of Class of Securities:

(a)

Common Shares, par value (euro)0.12 per share

Name of Issuer:

(b)

CureVac N.V.

Address of Issuer's Principal Executive Offices:

(c)

Friedrich-Miescher-Strasse 15, Tübingen, GERMANY , 72076.

Item 1 This Amendment is being filed to reflect the completion of the Reporting Persons' exchange all of the Shares
Comment: beneficially owned by them pursuant to an exchange offer (the "Exchange Offer") made by BioNTech SE, a European stock corporation ("BioNTech"). This Amendment is the final amendment to the Schedule 13D by the Reporting Persons and constitutes an "exit filing" by them.

Item 4. Purpose of Transaction

The Reporting Persons have tendered all of their Shares into the Exchange Offer. The Exchange Offer expired as scheduled at 9:00 a.m. Eastern Time on December 3, 2025. The Shares tendered by the Reporting Persons were accepted for exchange and transferred to BioNTech in a capital increase for the issue of shares in BioNTech underlying the American Depositary Shares of BioNTech offered as consideration of the Exchange Offer which took effect upon registration on December 10, 2025. As a result, the Reporting Persons no longer beneficially own, or otherwise hold, any securities of the Issuer. The Reporting Persons expect to receive full consideration to which they are entitled under the Exchange Offer (the "Completion") on or about December 15, 2025.

Item 5. Interest in Securities of the Issuer

(a) The information required by Items 5(a) and (b) is set forth in Rows 7 - 13 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. The Reporting Persons tendered all of their Shares in the Exchange Offer and, as a result of the issuance by BioNTech of its securities in the Exchange Offer on December 10, 2025, the Reporting Persons no longer beneficially own any Shares.

- (b) The information required by Items 5(a) and (b) is set forth in Rows 7 - 13 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.
- (c) Other than the transaction described in Item 5(a) no Reporting Person has effected any transaction in the Shares during the past sixty (60) days
- (d) Not applicable.
- (e) December 10, 2025.

Item 7. Material to be Filed as Exhibits.

99.1 Power of Attorney (Incorporated by reference to Exhibit 1 to Amendment No. 5 to Schedule 13D filed by the Reporting Persons with the SEC on May 5, 2022). 99.2 Joint Filing Agreement (Incorporated by reference to Exhibit 2 to Amendment No. 5 to Schedule 13D filed by the Reporting Persons with the SEC on May 5, 2022).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

MH-LT-Investments GmbH

Signature: /s/ Dr. Christina Eschenfelder
Name/Title: Dr. Christina Eschenfelder/Attorney-in-fact
Date: 12/12/2025

Dr. Matthias Hothum

Signature: /s/ Dr. Christina Eschenfelder as attorney-in-fact
Name/Title: MATTHIAS HOTHUM
Date: 12/12/2025